Duality Biotherapeutics, Inc. (9606) Price & Analysis

Compare

2 Followers

9606 Stock Chart & Stats

Day’s Range― - ―

52-Week RangeHK$165.50 - HK$563.50

Previous CloseN/A

VolumeN/A

Average Volume (3M)740.57K

Market Cap

HK$34.95B

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta1.85

Next Earnings

Aug 26, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding88,036,260

10 Day Avg. Volume1,644,010

30 Day Avg. Volume740,574

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

HK$367.06

Price Target Upside-7.54% Downside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Financial PositionThe company maintains a solid cash balance of RMB3.75bn, which is sufficient to support continued R&D and pipeline expansion.

Industry RecognitionDualityBio's high-profile partnerships serve as industry validation of its platform and pipeline assets.

PartnershipsDualityBio's extensive partnerships with companies like BioNTech and GSK, totaling over US$6.0bn in potential deal value, are expected to provide sustained funding as clinical programs progress.

Pipeline InnovationDualityBio has a robust pipeline of in-house discovered antibody-drug conjugate (ADC) candidates which is a testament to the Company's prowess in ADC innovation.

Bears Say

Commercialization TimelineBioNtech and DualityBio plan to file NDAs for DB-1303/BNT323 in the US and China by end-2025, marking a major step towards commercialization.

Duality Biotherapeutics, Inc. News

Duality Biotherapeutics Gains Inclusion in Key Stock Indices

The latest update is out from Duality Biotherapeutics, Inc. ( ($HK:9606) ). Duality Biotherapeutics, Inc., a company incorporated...

15d ago

9606

Duality Biotherapeutics Achieves Key Milestone in Cancer Drug Trial

Duality Biotherapeutics, Inc. ( ($HK:9606) ) has shared an announcement. Duality Biotherapeutics, Inc. announced that its Phase III...

17d ago

9606

Duality Biotherapeutics, Inc.: Strong Growth Potential and Innovation Drive Buy Rating

Duality Biotherapeutics, Inc., the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jill Wu...

21d ago

Duality Biotherapeutics Reports Strong Pipeline Progress Amid Financial Losses

Duality Biotherapeutics, Inc. ( ($HK:9606) ) has provided an update. Duality Biotherapeutics, Inc. announced its interim results for...

27d ago

9606

Duality Biotherapeutics Schedules Board Meeting for Interim Results

Duality Biotherapeutics, Inc. ( ($HK:9606) ) has shared an announcement. Duality Biotherapeutics, Inc. has announced a board meeting...

1M ago

9606

Duality Biotherapeutics’ DB-1310 Receives FDA Fast Track Designation

An update from Duality Biotherapeutics, Inc. ( ($HK:9606) ) is now available. Duality Biotherapeutics, Inc. has announced that...

2M ago

9606

Duality Biotherapeutics Secures Shareholder Approval for Key Resolutions at AGM

Duality Biotherapeutics, Inc. ( ($HK:9606) ) has provided an announcement. Duality Biotherapeutics, Inc. announced the successful passage of...

3M ago

9606

Duality Biotherapeutics Addresses Stock Fluctuations Post-Data Release

Duality Biotherapeutics, Inc. ( ($HK:9606) ) has shared an announcement. Duality Biotherapeutics, Inc. has addressed recent fluctuations in...

3M ago

9606

Promising Investment Opportunity in Duality Biotherapeutics: Strong ADC Pipeline and Strategic Partnerships Justify Buy Rating

Duality Biotherapeutics, Inc. (9606) has received a new Buy rating, initiated by CMB International Securities analyst, Jill Wu....

4M ago

Duality Biotherapeutics Announces AGM and Key Resolutions for 2025

An announcement from Duality Biotherapeutics, Inc. ( ($HK:9606) ) is now available. Duality Biotherapeutics, Inc. has announced its...

4M ago

9606

9606 FAQ

What was Duality Biotherapeutics, Inc.’s price range in the past 12 months?

Duality Biotherapeutics, Inc. lowest stock price was HK$165.50 and its highest was HK$563.50 in the past 12 months.

What is Duality Biotherapeutics, Inc.’s market cap?

Duality Biotherapeutics, Inc.’s market cap is HK$34.95B.

When is Duality Biotherapeutics, Inc.’s upcoming earnings report date?

Duality Biotherapeutics, Inc.’s upcoming earnings report date is Aug 26, 2025 which is 27 days ago.

How were Duality Biotherapeutics, Inc.’s earnings last quarter?

Duality Biotherapeutics, Inc. released its earnings results on Aug 26, 2025. The company reported -HK$54.272 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$54.272.

Is Duality Biotherapeutics, Inc. overvalued?

According to Wall Street analysts Duality Biotherapeutics, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Duality Biotherapeutics, Inc. pay dividends?

Duality Biotherapeutics, Inc. does not currently pay dividends.

What is Duality Biotherapeutics, Inc.’s EPS estimate?

Duality Biotherapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Duality Biotherapeutics, Inc. have?

Duality Biotherapeutics, Inc. has 88,036,260 shares outstanding.

What happened to Duality Biotherapeutics, Inc.’s price movement after its last earnings report?

Duality Biotherapeutics, Inc. reported an EPS of -HK$54.272 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.906%.

Which hedge fund is a major shareholder of Duality Biotherapeutics, Inc.?

Currently, no hedge funds are holding shares in HK:9606

Duality Biotherapeutics, Inc. Stock Smart Score

Neutral

Analyst Consensus

Moderate Buy

Average Price Target:
HK$367.06 (-7.54% Downside)

News Sentiment

Neutral

Bullish news 50%
Bearish news 100%

Top Smart Score Stocks >

Company Description

Duality Biotherapeutics, Inc.

Duality Biotherapeutics, Inc. operates as a clinical stage company. It focuses on the development of next generation antibody-drug conjugate therapeutics and duality immune toxin antibody conjugate therapeutic. The company was founded by Zhu Zhong Yuan on July 3, 2019 and is headquartered in Shanghai, China.

Duality Biotherapeutics, Inc. (9606) Earnings & Revenues

Historic Earnings Reports

9606 Stock 12 Month Forecast

Average Price Target

HK$367.06

▼(-7.54% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"186":"HK$186","277":"HK$277","368":"HK$368","231.5":"HK$231.5","322.5":"HK$322.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":367.06,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$367.06</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":367.06,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$367.06</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":367.06,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$367.06</span>\n  </div></div>","useHTML":true}}],"tickPositions":[186,231.5,277,322.5,368],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"May<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,349.2,350.57384615384615,351.9476923076923,353.32153846153847,354.6953846153846,356.0692307692308,357.44307692307694,358.81692307692305,360.1907692307692,361.56461538461537,362.9384615384615,364.3123076923077,365.68615384615384,{"y":367.06,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,349.2,350.57384615384615,351.9476923076923,353.32153846153847,354.6953846153846,356.0692307692308,357.44307692307694,358.81692307692305,360.1907692307692,361.56461538461537,362.9384615384615,364.3123076923077,365.68615384615384,{"y":367.06,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,349.2,350.57384615384615,351.9476923076923,353.32153846153847,354.6953846153846,356.0692307692308,357.44307692307694,358.81692307692305,360.1907692307692,361.56461538461537,362.9384615384615,364.3123076923077,365.68615384615384,{"y":367.06,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":187.2,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":187.2,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":187.2,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":187.2,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":187.2,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":187.2,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":187.2,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":187.2,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":207.4,"date":1746057600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":207.4,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":195,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":324.8,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":349.2,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >